Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Abstract: In an information providing method, purchase data indicating a purchase history of a control customer is acquired, and a merchandise category to which at least one merchandise belongs is determined from the purchase data. In this method, an extent of a potential health symptom of a target customer is further predicted using a health predictive model having the merchandise category to which at least one merchandise included in the purchase history belongs and an extent of the health symptom correlated therein, and the merchandise category. In the method, health information indicating the extent of the predicted health symptom is provided to the target customer.

Abstract: An object of the present invention is to provide a standard substance for quantification of PSA having a specific sugar chain that can be used in a general purpose quantification, wherein the standard substance has less unbalanced sugar chain expression patterns, can be manufactured with high reproducibility, and enables the quantification of patient's sample comprising a high concentration of PSA, and preparation method therefor, standard solution for PSA quantification, and PSA quantification method. The standard substance comprises a compound having the structure of a PSA with a sugar chain represented by any of the following formulae A to D, and is isolated and purified from a natural product, chemically or enzymatically altered from a natural product, or the compound is artificially synthesized.

Abstract: Provided is a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I): wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.

Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.

Abstract: In some embodiments, a system includes an ingestible signal generator coupled to a medication and configured to generate a body-transmissible signal upon ingestion by a user. The system also includes a receiver, the receiver including a sensor configured to detect the body-transmissible signal, the receiver configured to generate and wirelessly transmit a sensor signal based on the body-transmissible signal. The system also includes a user device. A processor of the user device is configured to wirelessly monitor the sensor for the sensor signal and, in response to not receiving the sensor signal within a predetermined time period, generate a notification. The processor is further configured to send a signal to present the notification and receive a response to the notification from the user. The processor is also configured to identify at least one trend associated with the sensor signal and the medication, and perform an action based thereon.

Abstract: A method for detecting an analyte according to the present invention includes: a first step of supplying a specimen to a detection device having a first ligand that is immobilized on a substrate and is capable of specifically binding to the analyte, the specimen being supplied onto the substrate of the detection device, and then causing the analyte included in the specimen to bind to the first ligand; a second step of supplying, onto the substrate, a second ligand that is labeled with a marker and is capable of specifically binding to the analyte, and then causing the second ligand to bind to the analyte bound to the first ligand; and a third step of measuring the second ligand bound to the analyte, wherein in the second step, carboxymethyl dextran is supplied onto the substrate.

Abstract: Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5) wherein the crystal has peaks at diffraction angles 2?(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using CuK? characteristic X-rays.

Abstract: [Problem] To ensure that a fluid is prevented from overflowing from a well and exposing the user to a biohazard. [Solution] A cartridge for use in measuring a component to be measured contained in a fluid includes a recessed well, formed for storing the fluid, the well including: a lower barrel portion that defines a lower space having a closed bottom; and an upper barrel portion that is formed above the lower barrel portion and defines an upper space having an opening on the top end, wherein a step portion is formed between the lower barrel portion and the upper barrel portion, the step portion being formed on an inner wall surface of the well and defining a step that continuously connects the inner wall surface of the lower barrel portion and the inner wall surface of the upper barrel portion.

Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.

Abstract: The present invention further provides a composition for inhibiting purine body absorption, a composition for inhibiting purine nucleotide metabolism, a composition for inhibiting phosphatase, a composition for inhibiting uric acid level elevation, a composition for improving blood pressure, a composition for improving blood glucose level, a composition for improving liver function, a composition for controlling serum iron level, or a composition for promoting calcium absorption, comprising an inositol phosphate or a salt thereof. The present invention further provides a composition comprising an inositol phosphate or a salt thereof, wherein the taste thereof is improved by adding thereto a predetermined amount of calcium lactate.

Abstract: The present invention relates to a prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.

Abstract: A pharmaceutical product including a housing that defines a cavity, wherein the cavity stores a pharmaceutical material, and wherein the housing comprises a material configured to dissolve based on contact with a fluid, an ingestible device to encode information in a current signature, wherein the ingestible device is positioned within the housing, and a protective material that encompasses the ingestible device. The ingestible device may be attached to a flexible component, wherein the flexible component is configured to releasably secure the ingestible device within the housing.

Abstract: A compound of formula (I): wherein Ring A, Q, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X, a, b, c and d are as defined in the specification.

Abstract: Methods, devices and systems for acquiring information useful to support a patient in implementing and adhering to a medically prescribed therapy plan are provided. The therapy may incorporate biofeedback methods and/or personalized therapy aspects. A method includes steps of receiving, by a receiving device, biometric information associated with an ingestible event marker; analyzing, by a computing device having a microprocessor configured to perform a biometric information analysis, the biometric information; and determining a therapeutic recommendation at least partly on the basis of the analysis and/or integrating biofeedback techniques into patient therapy or activity. A system includes a biometric information module to receive biometric information associated with an ingestible event marker; an analysis module to analyze the biometric information; and a determination module to optionally determine and communicate a therapeutic recommendation at least partly on the basis of the analysis.

Abstract: The present invention provides a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I): wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.

Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.

Abstract: An apparatus that includes a partial power source including a first material and a second material, the partial power source configured to generate, upon contact with a conducting medium, a potential difference between the first material and the second material to provide power to a control device, and generate, using the first material and the second material, a current flow within the conducting medium, the current flow including information encoded based on a variable conductance between the first material and the second material.

Abstract: Controlled activation identifiers for use in ingestible compositions, such as pharma-informatics enabled compositions, are provided. The identifiers include a controlled activation element that provides for activation of the identifier in response to the presence of a predetermined stimulus at a target site of interest. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc.

Abstract: A detection method uses a reaction vessel including a container including a housing part having a first opening opened at an upper portion and a second opening opened at a side portion, and a side wall member fixed to the container so that a capturing region on a metal film is exposed in the second opening. First, a liquid containing a specimen is provided to the housing part. Next, the liquid in the housing part is stirred to capture, into the capturing region, a substance to be detected in the liquid. Next, the metal film is irradiated with light so that surface plasmon resonance occurs in the metal film, and light emitted from the reaction vessel and having a light amount changing depending on the amount of the substance to be detected captured in the capturing region is detected.